Welcome to our dedicated page for Axsome Therapeut SEC filings (Ticker: AXSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Axsome Therapeutics, Inc. (NASDAQ: AXSM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a biopharmaceutical issuer focused on central nervous system (CNS) conditions, Axsome uses its SEC reports to communicate financial results, product revenue for AUVELITY, SUNOSI, and SYMBRAVO, and updates on its development pipeline, which includes programs such as AXS-05, AXS-12, AXS-14, solriamfetol in new indications, and AZD7325.
Among the filings, Form 8-K current reports are especially relevant for tracking material events. For example, Axsome has filed 8-Ks to furnish press releases announcing quarterly financial results and to disclose updates such as the receipt of a Paragraph IV Certification Notice Letter regarding a proposed generic version of SYMBRAVO. These documents help investors understand how clinical progress, intellectual property developments, and commercial performance affect the company.
In addition to 8-Ks, investors typically review Axsome’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which contain detailed discussions of net product revenue, research and development spending, selling and administrative expenses, risk factors, and descriptions of the company’s CNS portfolio and pipeline. Proxy statements and, when applicable, Forms 3, 4, and 5 can provide information on insider holdings and transactions, while registration statements and prospectuses outline capital-raising activities.
Stock Titan enhances these filings with AI-powered summaries that explain the key points of lengthy documents such as 10-Ks, 10-Qs, and major 8-Ks in plain language. Real-time EDGAR updates help ensure that new Axsome filings appear promptly, and AI-generated highlights can make it easier to locate information on topics such as AXS-05’s regulatory status, AXS-12’s Orphan Drug Designation, or revenue trends for AUVELITY, SUNOSI, and SYMBRAVO without reading every page of the underlying filing.
Notice of proposed sale of common stock by an insider. The filing reports a proposed sale of 19,220 shares of common stock through Goldman Sachs & Co. LLC with an aggregate market value of
Mark L. Jacobson, Chief Operating Officer and director of Axsome Therapeutics (AXSM), reported option exercise and a subsequent sale on 09/22/2025. He exercised 10,000 stock options with an exercise price of $2.85 per share, acquiring 10,000 shares. Those shares were then sold in open market transactions at a weighted average price of $115.96 per share, leaving him with 0 shares beneficially owned following the transactions. The filing states the exercise was necessary because the options were reaching their 10-year expiration and that both the exercise and sale were made pursuant to a pre-approved Rule 10b5-1 plan which has now completed.
Axsome Therapeutics, Inc. (AXSM) Form 144 notice reports a proposed sale of 10,000 common shares through Charles Schwab with an aggregate market value of $1,159,571, based on approximately 49,901,487 shares outstanding. The shares were acquired on 09/22/2025 through an employee stock option exercise and the payment method is listed as a broker payment for cashless exercise. The filing also discloses a prior sale by Mark L. Jacobson of 45,783 shares on 09/16/2025 generating $5,241,305 in gross proceeds. The filer affirms no undisclosed material adverse information and includes standard Rule 144 representations.
Mark L. Jacobson, Chief Operating Officer of Axsome Therapeutics, Inc. (AXSM), reported option exercises and open-market sales on 09/16/2025. He exercised two stock option grants: 25,000 shares at $4.95 (issued 03/15/2018) and 15,000 shares at $4.85 (issued 09/13/2018), generating 40,000 underlying shares. All 40,000 shares were subsequently sold in open-market transactions under a pre-approved 10b5-1 plan for weighted average prices of $116.19 and $114.23, resulting in no shares owned following the sales. The exercises were necessary due to the options approaching their 10-year expiration.
Axsome Therapeutics insider activity by Herriot Tabuteau: The reporting person, who is CEO, director and a 10% owner, executed option exercises on 09/12/2025, 09/15/2025 and 09/16/2025 to purchase in aggregate 62,880 shares at exercise prices of $118.96, $117.37 and $114.19 respectively, under options originally granted 05/27/2017 and exercisable through 05/27/2026. Those exercises were followed by open-market sales of the same underlying shares pursuant to a pre-approved 10b5-1 plan, with weighted-average sale prices ranging roughly $113.01 to $122.54. The filer reports indirect beneficial ownership of 7,344,500 shares through an entity for which he has voting and dispositive power.
Axsome Therapeutics, Inc. (AXSM) filed a Form 144 reporting a proposed sale of 45,783 common shares with an aggregate market value of $5,241,305.00. The filing lists Charles Schwab & Co., Inc. as the broker and names NASDAQ as the exchange, with an approximate sale date of 09/16/2025. The seller acquired 5,783 shares on 05/29/2024 via exercise and hold paid in cash, and 40,000 shares on 09/16/2025 via an employee stock option exercise using a broker cashless exercise. The filer certifies no undisclosed material adverse information.
Axsome Therapeutics (AXSM) reported a Form 144 notice showing a proposed sale of 19,719 shares of common stock through Goldman Sachs & Co. LLC, with an aggregate market value of $2,249,937.90, and an approximate sale date of 09/16/2025 on NASD. The securities were acquired on 05/27/2016 as compensation via stock options and the stated payment method is a cashless exercise/same-day sale. The filing also discloses two prior sales by the same person within the past three months: 27,907 shares sold on 09/12/2025 for $3,319,894.86 and 15,254 shares sold on 09/15/2025 for $1,790,378.76. The filer affirms no undisclosed material adverse information.
Axsome Therapeutics (AXSM) reported an insider notice to sell common stock under Rule 144. The filing shows 15,254 shares proposed for sale through Goldman Sachs with an aggregate market value of $1,781,285.85, and the sale date is listed as 09/15/2025. The shares were acquired on 05/27/2016 as compensation from the issuer via stock options and the payment method is described as a cashless exercise/same-day sale. The filing also discloses a separate sale on 09/12/2025 by Herriot Tabuteau of 27,907 shares for gross proceeds of $3,319,894.86. The form includes the standard representation that the seller does not possess undisclosed material adverse information.
Axsome Therapeutics, Inc. (AXSM) director Mark Coleman reported open-market purchases of the issuer's common stock on 09/08/2025. The Form 4 lists three purchase transactions totaling 1,575 shares at prices of $127.20, $127.30, and $127.40, recorded as purchases. After these transactions Mr. Coleman is reported to beneficially own 48,212 shares directly. The filing also discloses 403,856 shares held indirectly by an entity over which he has voting and dispositive power, for a combined reported beneficial interest of 452,068 shares as shown on the form. The purchases were executed in the open market and the Form 4 was signed by an attorney-in-fact on 09/09/2025. Footnotes clarify the open-market nature of the purchases and the basis for indirect beneficial ownership.
Axsome Therapeutics director Mark E. Saad executed and sold shares on 09/05/2025 under a pre-approved 10b5-1 plan. He exercised stock options to purchase 9,127 shares at an exercise price of $9.00 per share, then sold the 9,127 underlying shares in open market transactions at a weighted average price of $125.07. After these transactions the reporting person beneficially owned 10,002 shares directly and 300 shares indirectly (held in custodial UTMA accounts).